Gilead Sciences, Inc. (GILD) 2 Wins for Gilead: HIV Present, HCV Future

Gilead Sciences, Inc. (NASDAQ:GILD) commands the frontrunner position in the all-oral combo race. The company submitted an NDA for its combo in April. A decision from the FDA is due by Dec. 8. Most analysts project peak annual sales of $5 billion to $7 billion for Gilead’s HCV regimen, although Michael Yee with RBC Capital suspects those estimates could be low.

Expansion into the world of oncology is on its way, also. Gilead Sciences, Inc. (NASDAQ:GILD)’s chief scientific officer, Norbert Bischofberger, says that the company plans to submit for regulatory approval of non-Hodgkin’s lymphoma drug idelalisib in late 2013.

Gilead Sciences, Inc. (NASDAQ:GILD) looks to be a good pick in my view. Analysts expect annual earnings growth of 26% over the next few years. With strength in HIV now, and HCV in the not-too-distant future, I’d say Gilead will remain a winner.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.